En español
NIDA

Medication Development

Dr. Phil Skolnick Now Leads NIDA's Medications Development Efforts

Announces the appointment of Dr. Phil Skolnick as NIDA’s director of the Division of Pharmacotherapies and Medical Consequences of Drug Abuse.

Three Scientists Join Advisory Council

Announces three new NIDA National Advisory Council on Drug Abuse members and describes their drug abuse and addiction research experience.

Modafinil Normalizes Sleep During Early Cocaine Abstinence

Describes a study investigating the effectiveness of modafinil in enhancing sleep among cocaine abusers who are currently abstinent.

Neuropeptide Promotes Behaviors Tied to Addiction and Overeating

Reports on several studies implicating a certain neuropeptide (a signaling molecule) in fostering addition and overeating and discusses implications for addiction treatment.

NIDA Appoints New Director of the Intramural Research Program

Announces NIDA’s new director of its intramural research program, Antonello Bonci, M.D., a leading researcher in neuropsychopharmacology.

Cocaine Vaccine Helps Some Reduce Drug Abuse

Reports on the results of a clinical trial that tested the effectiveness of a cocaine vaccine designed as a therapy for cocaine abuse and plans underway for a new study of 300 patients to confirm these results.

Pages

Subscribe to Medication Development